Product Code: TMRGL40970
The report provides revenue of the global anticoagulant reversal drugs market for the period 2017-2031, considering 2021 as the base year and 2031 as the forecast year. The report also provides the compound annual growth rate (CAGR %) of the global anticoagulant reversal drugs market from 2022 to 2031.
The report has been prepared after an extensive research. Primary research involved bulk of the research efforts, wherein analysts carried out interviews with key opinion leaders, industry leaders, and opinion makers. Secondary research involved referring to key players' product literature, annual reports, press releases, and relevant documents to understand the anticoagulant reversal drugs market.
The report delves into the competitive landscape of the global anticoagulant reversal drugs market. Key players operating in the global anticoagulant reversal drugs market have been identified and each one of these has been profiled, in terms of various attributes. Company overview, financial standings, recent developments, and SWOT are attributes of players in the global anticoagulant reversal drugs market profiled in this report.
Table of Contents
1. Preface
- 1.1. Market Definition and Scope
- 1.2. Market Segmentation
- 1.3. Key Research Objectives
- 1.4. Research Highlights
2. Assumptions and Research Methodology
3. Executive Summary: Global Anticoagulant Reversal Drugs Market
4. Market Overview
- 4.1. Introduction
- 4.1.1. Definition
- 4.1.2. Industry Evolution / Developments
- 4.2. Overview
- 4.3. Market Dynamics
- 4.3.1. Drivers
- 4.3.2. Restraints
- 4.3.3. Opportunities
- 4.4. Global Anticoagulant Reversal Drugs Market Analysis and Forecast, 2017-2031
5. Key Insights
- 5.1. Key Industry Developments (mergers & acquisitions, product launches, partnerships)
- 5.2. Pipeline Analysis
- 5.3. Reimbursement Scenario by Region/globally
- 5.4. Regulatory Scenario by Region/Globally
- 5.5. Covid-19 Pandemic Impact on the Industry
6. Global Anticoagulant Reversal Drugs Market Analysis and Forecast, by Product
- 6.1. Introduction & Definition
- 6.2. Key Findings / Developments
- 6.3. Market Value Forecast, by Product, 2017-2031
- 6.3.1. Prothrombin Complex Concentrates
- 6.3.2. Vitamin K
- 6.3.3. Protamine
- 6.3.4. Tranexamic Acid
- 6.3.5. Idarucizumab
- 6.3.6. AndeXXa
- 6.3.7. Others
- 6.4. Market Attractiveness Analysis, by Product
7. Global Anticoagulant Reversal Drugs Market Analysis and Forecast, by Distribution Channel
- 7.1. Introduction & Definition
- 7.2. Key Findings / Developments
- 7.3. Market Value Forecast, by Distribution Channel, 2017-2031
- 7.3.1. Hospital Pharmacies
- 7.3.2. Retail Pharmacies
- 7.3.3. Others
- 7.4. Market Attractiveness Analysis, by Distribution Channel
8. Global Anticoagulant Reversal Drugs Market Analysis and Forecast, by Region
- 8.1. Key Findings
- 8.2. Market Value Forecast, by Region
- 8.2.1. North America
- 8.2.2. Europe
- 8.2.3. Asia Pacific
- 8.2.4. Latin America
- 8.2.5. Middle East & Africa
- 8.3. Market Attractiveness Analysis, by Region
9. North America Anticoagulant Reversal Drugs Market Analysis and Forecast
- 9.1. Introduction
- 9.2. Market Value Forecast, by Product, 2017-2031
- 9.2.1. Prothrombin Complex Concentrates
- 9.2.2. Vitamin K
- 9.2.3. Protamine
- 9.2.4. Tranexamic Acid
- 9.2.5. Idarucizumab
- 9.2.6. AndeXXa
- 9.2.7. Others
- 9.3. Market Value Forecast, by Distribution Channel, 2017-2031
- 9.3.1. Hospital Pharmacies
- 9.3.2. Retail Pharmacies
- 9.3.3. Others
- 9.4. Market Value Forecast, by Country, 2017-2031
- 9.4.1. U.S.
- 9.4.2. Canada
- 9.5. Market Attractiveness Analysis
- 9.5.1. By Product
- 9.5.2. By Distribution Channel
- 9.5.3. By Country
10. Europe Anticoagulant Reversal Drugs Market Analysis and Forecast
- 10.1. Introduction
- 10.2. Market Value Forecast, by Product, 2017-2031
- 10.2.1. Prothrombin Complex Concentrates
- 10.2.2. Vitamin K
- 10.2.3. Protamine
- 10.2.4. Tranexamic Acid
- 10.2.5. Idarucizumab
- 10.2.6. AndeXXa
- 10.2.7. Others
- 10.3. Market Value Forecast, by Distribution Channel, 2017-2031
- 10.3.1. Hospital Pharmacies
- 10.3.2. Retail Pharmacies
- 10.3.3. Others
- 10.4. Market Value Forecast, by Country/Sub-region, 2017-2031
- 10.4.1. Germany
- 10.4.2. U.K.
- 10.4.3. France
- 10.4.4. Italy
- 10.4.5. Spain
- 10.4.6. Rest of Europe
- 10.5. Market Attractiveness Analysis
- 10.5.1. By Product
- 10.5.2. By Distribution Channel
- 10.5.3. By Country/Sub-region
11. Asia Pacific Anticoagulant Reversal Drugs Market Analysis and Forecast
- 11.1. Introduction
- 11.2. Market Value Forecast, by Product, 2017-2031
- 11.2.1. Prothrombin Complex Concentrates
- 11.2.2. Vitamin K
- 11.2.3. Protamine
- 11.2.4. Tranexamic Acid
- 11.2.5. Idarucizumab
- 11.2.6. AndeXXa
- 11.2.7. Others
- 11.3. Market Value Forecast, by Distribution Channel, 2017-2031
- 11.3.1. Hospital Pharmacies
- 11.3.2. Retail Pharmacies
- 11.3.3. Others
- 11.4. Market Value Forecast, by Country/Sub-region, 2017-2031
- 11.4.1. China
- 11.4.2. Japan
- 11.4.3. India
- 11.4.4. Australia & New Zealand
- 11.4.5. Rest of Asia Pacific
- 11.5. Market Attractiveness Analysis
- 11.5.1. By Product
- 11.5.2. By Distribution Channel
- 11.5.3. By Country/Sub-region
12. Latin America Anticoagulant Reversal Drugs Market Analysis and Forecast
- 12.1. Introduction
- 12.2. Market Value Forecast, by Product, 2017-2031
- 12.2.1. Prothrombin Complex Concentrates
- 12.2.2. Vitamin K
- 12.2.3. Protamine
- 12.2.4. Tranexamic Acid
- 12.2.5. Idarucizumab
- 12.2.6. AndeXXa
- 12.2.7. Others
- 12.3. Market Value Forecast, by Distribution Channel, 2017-2031
- 12.3.1. Hospital Pharmacies
- 12.3.2. Retail Pharmacies
- 12.3.3. Others
- 12.4. Market Value Forecast, by Country/Sub-region, 2017-2031
- 12.4.1. Brazil
- 12.4.2. Mexico
- 12.4.3. Rest of Latin America
- 12.5. Market Attractiveness Analysis
- 12.5.1. By Product
- 12.5.2. By Distribution Channel
- 12.5.3. By Country/Sub-region
13. Middle East & Africa Anticoagulant Reversal Drugs Market Analysis and Forecast
- 13.1. Introduction
- 13.2. Market Value Forecast, by Product, 2017-2031
- 13.2.1. Prothrombin Complex Concentrates
- 13.2.2. Vitamin K
- 13.2.3. Protamine
- 13.2.4. Tranexamic Acid
- 13.2.5. Idarucizumab
- 13.2.6. AndeXXa
- 13.2.7. Others
- 13.3. Market Value Forecast, by Distribution Channel, 2017-2031
- 13.3.1. Hospital Pharmacies
- 13.3.2. Retail Pharmacies
- 13.3.3. Others
- 13.4. Market Value Forecast, by Country/Sub-region, 2017-2031
- 13.4.1. GCC Countries
- 13.4.2. South Africa
- 13.4.3. Rest of Middle East & Africa
- 13.5. Market Attractiveness Analysis
- 13.5.1. By Product
- 13.5.2. By Distribution Channel
- 13.5.3. By Country/Sub-region
14. Competition Landscape
- 14.1. Market Player - Competition Matrix (By Tier and Size of companies)
- 14.2. Market Share Analysis By Company (2021)
- 14.3. Company Profiles
- 14.3.1. Amneal Pharmaceuticals, Inc.
- 14.3.1.1. Company Overview (HQ, Business Segments, Employee Strength)
- 14.3.1.2. Product Portfolio
- 14.3.1.3. SWOT Analysis
- 14.3.1.4. Financial Overview
- 14.3.1.5. Strategic Overview
- 14.3.2. Bausch Health Companies, Inc.
- 14.3.2.1. Company Overview (HQ, Business Segments, Employee Strength)
- 14.3.2.2. Product Portfolio
- 14.3.2.3. SWOT Analysis
- 14.3.2.4. Financial Overview
- 14.3.2.5. Strategic Overview
- 14.3.3. Boehringer Ingelheim GmbH
- 14.3.3.1. Company Overview (HQ, Business Segments, Employee Strength)
- 14.3.3.2. Product Portfolio
- 14.3.3.3. SWOT Analysis
- 14.3.3.4. Financial Overview
- 14.3.3.5. Strategic Overview
- 14.3.4. CSL Limited
- 14.3.4.1. Company Overview (HQ, Business Segments, Employee Strength)
- 14.3.4.2. Product Portfolio
- 14.3.4.3. SWOT Analysis
- 14.3.4.4. Financial Overview
- 14.3.4.5. Strategic Overview
- 14.3.5. Fresenius Kabi AG
- 14.3.5.1. Company Overview (HQ, Business Segments, Employee Strength)
- 14.3.5.2. Product Portfolio
- 14.3.5.3. SWOT Analysis
- 14.3.5.4. Financial Overview
- 14.3.5.5. Strategic Overview
- 14.3.6. Perosphere Pharmaceuticals, Inc.
- 14.3.6.1. Company Overview (HQ, Business Segments, Employee Strength)
- 14.3.6.2. Product Portfolio
- 14.3.6.3. SWOT Analysis
- 14.3.6.4. Financial Overview
- 14.3.6.5. Strategic Overview
- 14.3.7. Pfizer, Inc.
- 14.3.7.1. Company Overview (HQ, Business Segments, Employee Strength)
- 14.3.7.2. Product Portfolio
- 14.3.7.3. SWOT Analysis
- 14.3.7.4. Financial Overview
- 14.3.7.5. Strategic Overview
- 14.3.8. Portola Pharmaceuticals, Inc.
- 14.3.8.1. Company Overview (HQ, Business Segments, Employee Strength)
- 14.3.8.2. Product Portfolio
- 14.3.8.3. SWOT Analysis
- 14.3.8.4. Financial Overview
- 14.3.8.5. Strategic Overview
- 14.3.9. Octapharma AG
- 14.3.9.1. Company Overview (HQ, Business Segments, Employee Strength)
- 14.3.9.2. Product Portfolio
- 14.3.9.3. SWOT Analysis
- 14.3.9.4. Financial Overview
- 14.3.9.5. Strategic Overview